Spectrum Pharmaceuticals (SPPI) Securities Lawsuit: New Lead Plaintiff Deadline Announced

San Francisco, California--(Newsfile Corp. - August 19, 2025) - A federal court has reopened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action, setting a new deadline of September 24, 2025. This comes after the previous lead plaintiff was disqualified in an order on August 4, 2025.

Hagens Berman urges Spectrum investors who suffered substantial losses to submit your losses now.

Class Period: Mar. 17, 2022 - Sept. 22, 2022
Lead Plaintiff Deadline: Sept. 24, 2025
Visit: www.hbsslaw.com/investor-fraud/sppi
Contact the Firm Now: SPPI@hbsslaw.com
844-916-0895

Background of the Lawsuit

The lawsuit, Christiansen v. Spectrum Pharmaceuticals, Inc., et al., has been ongoing since late 2022 and early 2023. At that time, multiple class actions were filed against the company, alleging that it made misleading statements about a drug called poziotinib. The court consolidated these cases and in March 2023, appointed an individual investor as the lead plaintiff. The case has since survived a motion to dismiss and moved into the discovery phase.

Now, with the lead plaintiff disqualified, the court is once again seeking a new representative for investors who purchased Spectrum stock between March 17, 2022, and September 22, 2022, and suffered losses.

The core of the litigation alleges that Spectrum repeatedly assured investors of positive data from its poziotinib clinical trial. However, the complaint claims the company omitted crucial information, including negative safety and efficacy data and the fact that it had not enrolled any patients in a required Phase 3 trial. These details were allegedly revealed when the FDA Oncologic Drugs Advisory Committee released a briefing document in September 2022, causing Spectrum's stock price to crash.

Your Opportunity to Act

National shareholders' rights firm Hagens Berman is investigating these claims. We encourage Spectrum (SPPI) investors who suffered significant losses to contact us about becoming the new lead plaintiff. As lead plaintiff, you would play a critical role in overseeing the litigation and protecting the interests of all class members.

If you'd like more information and answers to frequently asked questions about the Spectrum Pharmaceuticals case and our investigation, read more »

Whistleblowers: Persons with non-public information regarding Spectrum should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email SPPI@hbsslaw.com.

# # #

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/263150